Phase I Study of Farnesyl Transferase Inhibitor (BMS-214662) In Acute Leukemias, Myelodysplastic Syndromes And Chronic Myeloid Leukemia In Blast Phase
Latest Information Update: 06 Nov 2021
At a glance
- Drugs BMS 214662 (Primary)
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 30 Sep 2014 New trial record